Logo

Jazz Entered into an Exclusive License Agreement with Sumitomo Pharma to Develop and Commercialize DSP-0187 for the Treatment of Sleep Disorders

Share this
Jazz Entered into an Exclusive License Agreement with Sumitomo Pharma to Develop and Commercialize DSP-0187 for the Treatment of Sleep Disorders

Jazz Entered into an Exclusive License Agreement with Sumitomo Pharma to Develop and Commercialize DSP-0187 for the Treatment of Sleep Disorders

Shots:

  • Sumitomo to receive $50M up front & ~$1.09B in development, regulatory & commercial milestone along with royalty on net sales of DSP-0187
  • Jazz to get an exclusive license right to develop & commercialize DSP-0187 (orexin-2 receptor agonist) in the US, EU & other territories (Ex-Japan, China & other Asia/Pacific countries & regions) & continues to expand the neuroscience pipeline along with strong leadership for sleep disorder products. Sumitomo will obtain all development & commercialization rights
  • DSP-0187 is being studied in the P-I trial in Japan to evaluate safety, tolerability & PK in healthy volunteers. Jazz will continue to advance the development of DSP-0187, based on clinical studies

Ref: JazzPharma | Image: JazzPharma

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions